secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001683168-26-001461
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health CEO Jennifer Ernst resigns; Michael Handley appointed CEO to lead biopharma pivot
--------------------------------------------------------------------------------

- CEO Jennifer Ernst resigned March 2, 2026; board departure effective March 5; separation includes $325K cash severance, COBRA, equity vesting, and $50K restricted stock.
- Michael Handley appointed CEO and board member effective March 3; previously COO and President of Tivic Biopharma since February 2025.
- Handley brings over 20 years life sciences experience; led commercialization of 17 products, worked at Amgen and Genentech.
- Company shifts strategic focus to late-stage immunotherapies and biomanufacturing subsidiary Velocity Bioworks; highlights Entolimod as key asset.
- No dispute or disagreement with Ernst's resignation; Handley's existing employment agreement unchanged from February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826001461/0001683168-26-001461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826001461/tivic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer